In conclusion, here we proposed a novel therapeutic strategy for TP53-wt AML based on the synergistic combination of Nut-3a and WIP1i and unraveled the transcriptomic changes induced by WIP1i alone or in combination with Nut-3a in AML cells. This evidence concerns the gene TP53 and acute myeloid leukemia.